1. Home
  2. BRID vs ALXO Comparison

BRID vs ALXO Comparison

Compare BRID & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRID
  • ALXO
  • Stock Information
  • Founded
  • BRID 1932
  • ALXO 2015
  • Country
  • BRID United States
  • ALXO United States
  • Employees
  • BRID N/A
  • ALXO N/A
  • Industry
  • BRID Specialty Foods
  • ALXO Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRID Consumer Staples
  • ALXO Health Care
  • Exchange
  • BRID Nasdaq
  • ALXO Nasdaq
  • Market Cap
  • BRID 72.8M
  • ALXO 79.7M
  • IPO Year
  • BRID N/A
  • ALXO 2020
  • Fundamental
  • Price
  • BRID $7.55
  • ALXO $1.50
  • Analyst Decision
  • BRID
  • ALXO Strong Buy
  • Analyst Count
  • BRID 0
  • ALXO 6
  • Target Price
  • BRID N/A
  • ALXO $3.30
  • AVG Volume (30 Days)
  • BRID 3.3K
  • ALXO 353.4K
  • Earning Date
  • BRID 08-22-2025
  • ALXO 11-07-2025
  • Dividend Yield
  • BRID N/A
  • ALXO N/A
  • EPS Growth
  • BRID N/A
  • ALXO N/A
  • EPS
  • BRID N/A
  • ALXO N/A
  • Revenue
  • BRID $227,364,000.00
  • ALXO N/A
  • Revenue This Year
  • BRID N/A
  • ALXO N/A
  • Revenue Next Year
  • BRID N/A
  • ALXO N/A
  • P/E Ratio
  • BRID N/A
  • ALXO N/A
  • Revenue Growth
  • BRID N/A
  • ALXO N/A
  • 52 Week Low
  • BRID $7.24
  • ALXO $0.40
  • 52 Week High
  • BRID $10.83
  • ALXO $2.27
  • Technical
  • Relative Strength Index (RSI)
  • BRID 45.48
  • ALXO 51.15
  • Support Level
  • BRID $7.40
  • ALXO $1.29
  • Resistance Level
  • BRID $8.02
  • ALXO $1.66
  • Average True Range (ATR)
  • BRID 0.15
  • ALXO 0.20
  • MACD
  • BRID -0.01
  • ALXO 0.01
  • Stochastic Oscillator
  • BRID 39.12
  • ALXO 72.95

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: